FDA asks Lilly, Novo to remove suicide warnings from GLP-1 labels
FDA asks Lilly, Novo to remove suicide warnings from GLP-1 labels
Body unavailable. Use the original source.
FDA asks Lilly, Novo to remove suicide warnings from GLP-1 labels
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.